Back
BioXcel Therapeutics, Inc. 10K Form
Sell
21
BTAI
BioXcel Therapeutics, Inc.
Last Price:
$1.72
Seasonality Move:
59.54%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive BTAI News And Ratings
See the #1 stock for the next 7 days that we like better than BTAI
BTAI Financial Statistics
Sales & Book Value
| Annual Sales: | $2.3M |
|---|---|
| Cash Flow: | $-18.8M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-4.45 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -9.69770 |
|---|---|
| Net Income (TTM): | $-68.2M |
| Gross Margin: | $-186K |
| Return on Equity: | 0% |
| Return on Assets: | -173.67% |
BioXcel Therapeutics, Inc. Earnings Forecast
Key BioXcel Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 10 years for BTAI is -8.21%.
-
The Selling, General & Administrative Expenses for BTAI have been equal to 1,522.15% of Gross Profit Margin.
-
The Research & Development expenses have been 1,288.08% of Revenue.
-
The Net Earning history of BTAI is -2,630.14% of Total Revenues.
-
Per Share Earnings over the last 10 years have been positive in 0 years.
BioXcel Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BTAI |
| CUSIP: | 09075P |
| Website: | bioxceltherapeutics.com |
Debt
| Debt-to-Equity Ratio: | -1.23 |
|---|---|
| Current Ratio: | 1.17 |
| Quick Ratio: | 0.99 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BTAI Technical Analysis vs Fundamental Analysis
Sell
21
BioXcel Therapeutics, Inc. (BTAI)
is a Sell
Is BioXcel Therapeutics, Inc. a Buy or a Sell?
-
BioXcel Therapeutics, Inc. stock is rated a SellThe current BioXcel Therapeutics, Inc. [BTAI] share price is $1.73. The Score for BTAI is 21, which is 58% below its historic median score of 50, and infers higher risk than normal.